This $716,314 Project Grant (R01CA294689) awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal adenocarcinoma. The principal aims are to:
-
Use immune-competent mouse models of FGFR2-altered gastroesophageal cancer to develop and test highly efficacious FGFR2 biparatopic antibodies and antibody-drug conjugates, alone or in combination with immune checkpoint inhibitors.
-
Understand the mechanisms of resistance to FGFR2-selective tyrosine kinase inhibitors and develop combination strategies with FGFR2 biparatopic antibodies to delay the emergence of resistance.
The project includes a $120K sub-award to the Broad Institute to support pharmacokinetic studies and CRISPR screening for drugs that enhance FGFR2 inhibitor activity. The overall goal is to advance novel targeted and immune-based therapies for gastroesophageal cancers with FGFR2 alterations. The award period is from Jul 2024 to Jun 2029.
Generated 2/25/25, 5:00 AM